uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Oncology, Radiology and Clinical Immunology, Oncology.
Show others and affiliations
2002 (English)In: Medical Oncology, ISSN 1357-0560, Vol. 19, no 4, 277-80 p.Article in journal (Refereed) Published
Abstract [en]

Alemtuzumab (Campath-1H) is a humanized CD52 monoclonal antibody that targets normal as well as malignant B- and T-lymphocytes. Alemtuzumab has significant antitumor activity in chronic lymphocytic leukemia (B-CLL) but also induces immunosuppression. We describe a case of fatal adenovirus infection in a heavily pretreated patient with fludarabine-refractory B-CLL receiving alemtuzumab therapy, drawing attention to the fact that also viruses other than cytomegalovirus (CMV) and herpes simplex (HSV) need to be considered in B-CLL patients with fever of unknown origin while on alemtuzumab treatment.

Place, publisher, year, edition, pages
2002. Vol. 19, no 4, 277-80 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-105422DOI: 10.1385/MO:19:4:277PubMedID: 12512923OAI: oai:DiVA.org:uu-105422DiVA: diva2:221202
Available from: 2009-06-03 Created: 2009-06-03 Last updated: 2009-06-09Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed
By organisation
In the same journal
Medical Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 155 hits
ReferencesLink to record
Permanent link

Direct link